Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.
Research Center for Emergency and Disaster Resilience, Red Crescent Society of the Islamic Republic of Iran, Tehran, Iran.
J Prev Med Hyg. 2022 Dec 31;63(4):E618-E624. doi: 10.15167/2421-4248/jpmh2022.63.4.2731. eCollection 2022 Dec.
Hepatitis B virus (HBV) infection is a main challenge of the health system worldwide. Health policymakers in most countries attempt to help HBV patients by implementing support programs in addition to controlling HBV in their community so that the economic burden caused by HBV do not deprive the patients of accessing health services and reducing their quality of life. There are several health interventions for the prevention and control of HBV. Providing the first dose of the HBV vaccine within 24 hours after the infant is born is the most cost-effective way to prevent and control HBV. The purpose of this study is to review the nature of HBV, its epidemiology in Iran and worldwide, and to review the various policies and programs in Iran regarding the prevention and control of HBV, especially the use of vaccination. One of the goals of Sustainable Development Goals (SDGs) is to consider hepatitis as a threat to human health. In this regard, one of the top priorities of WHO is the prevention and control of HBV. In connection with the prevention of HBV, it is claimed that vaccination is the most effective and best intervention. Thus, vaccination in the safe's program of countries is highly recommended. According to the Ministry of Health and Medical Education (MOHME) reports, Iran has the lowest prevalence of HBV among the countries in Eastern Mediterranean Region Organization (EMRO). There is a hepatitis unit in MOHME whose responsibility is to coordinate and implement the hepatitis prevention and control programs. The HBV vaccine has been officially included in the vaccination program for children in Iran since 1993, and three doses of the vaccine are given to all infants. In 2007, during a large-scale program in Iran, 17-year-olds received the HBV vaccine, followed by adolescents born in 1990 and 1991. In recent years, the health system in Iran has made significant progress in preventing and controlling HBV. Over 95% coverage of the HBV vaccination is one of the achievements that have had a great impact on reducing the trend of HBV infection. In order to achieve the 2030 goals, the Iranian government, in addition to paying more attention to HBV elimination programs, should encourage other organizations to cooperate more effectively with MOHME.
乙型肝炎病毒 (HBV) 感染是全球卫生系统面临的主要挑战之一。大多数国家的卫生政策制定者试图通过在社区中控制 HBV 以外,还实施支持计划来帮助 HBV 患者,以避免 HBV 给患者带来的经济负担,使他们无法获得医疗服务并降低生活质量。有几种针对 HBV 的预防和控制的卫生干预措施。在婴儿出生后 24 小时内为其接种 HBV 疫苗第一针是预防和控制 HBV 的最具成本效益的方法。本研究的目的是回顾 HBV 的性质,其在伊朗和全球的流行病学,以及审查伊朗针对 HBV 的预防和控制的各种政策和计划,特别是疫苗接种的使用。可持续发展目标 (SDG) 的目标之一是将肝炎视为对人类健康的威胁。在这方面,世界卫生组织 (WHO) 的首要任务之一是预防和控制 HBV。在预防 HBV 方面,有人声称疫苗接种是最有效和最好的干预措施。因此,强烈建议在各国的安全计划中接种疫苗。根据卫生部和医疗教育部 (MOHME) 的报告,伊朗在东地中海地区组织 (EMRO) 的国家中 HBV 感染率最低。MOHME 有一个肝炎科,负责协调和实施肝炎预防和控制计划。HBV 疫苗自 1993 年以来已正式纳入伊朗儿童的免疫接种计划,所有婴儿都要接种三剂疫苗。2007 年,在伊朗的一次大规模计划中,为 17 岁的青少年接种了 HBV 疫苗,随后为 1990 年和 1991 年出生的青少年接种。近年来,伊朗卫生系统在预防和控制 HBV 方面取得了重大进展。HBV 疫苗接种覆盖率超过 95%,这是减少 HBV 感染趋势的一项重大成就。为了实现 2030 年的目标,伊朗政府除了更加关注 HBV 消除计划外,还应鼓励其他组织与 MOHME 更有效地合作。